78
Views
15
CrossRef citations to date
0
Altmetric
Review

Recent progress in the discovery of antagonists acting at P2X7 receptor

, &
Pages 271-287 | Published online: 22 Apr 2005
 

Abstract

The P2X7 receptor is involved in several processes relevant to inflammation (cytokine release, nitric oxide (NO) generation, killing of intracellular pathogens, cytotoxicity), thus, it may be an appealing target for pharmacological intervention. These findings prompted a number of drug companies, including AstraZeneca, King and Pfizer to initiate small-molecule programmes taking a number of different approaches, which are reviewed in this review article. The extensive use of high-throughput screening approaches, utilising diverse compound library sources, has lead to the identification of two important lead series (adamantane and benzenamide derivatives) acting on P2X7.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.